Phase 2 Rheumatoid arthritis trials recruiting now

All Rheumatoid arthritis trials, every phase

Other phases for Rheumatoid arthritis

Phase 2 Rheumatoid arthritis trials

• "Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
  NCT06915701 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Female · 2 locations
• A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
  NCT06671054 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
  NCT07118241 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 6 locations
• A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
  NCT06733935 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 18 locations
• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
  NCT06570798 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 58 locations
• A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
  NCT07737743 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 9 locations
• A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
  NCT06189495 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• A Study With CIT-013 in RA Patients
  NCT06567470 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
  NCT07412704 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 39 locations
• A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
  NCT07048197 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
  NCT07137598 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 63 locations
• A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
  NCT07409103 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 30 locations
• A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
  NCT06972446 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
  NCT07276581 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 144 locations
• AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
  NCT06991114 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis
  NCT07013110 · Phase: Phase 2 · Ages: 21 Years and older · Sex: All (male and female) · 1 location
• An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
  NCT07620392 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT
  NCT07062523 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  NCT06794008 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
  NCT06599658 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis
  NCT07745426 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)
  NCT07627893 · Phase: Phase 2, Phase 3 · Ages: 21 Years to 70 Years · Sex: All (male and female) · 1 location
• Controlling Hyperactive Immunity With Long-lived Lymphocytes
  NCT07473154 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Desloratadine as Adjunct Therapy for Rheumatoid Arthritis
  NCT07632872 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Dynamic Treatment Regiments for Glucocorticoid Tapering
  NCT06072768 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis
  NCT07566351 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis
  NCT07632846 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
  NCT07796516 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 47 locations
• FT839 in Autoimmune Diseases
  NCT07800871 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Fexofenadine in Patients With Active Rheumatoid Arthritis
  NCT05264025 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
• Fluorescence Imaging of IBD and RA Using Adalimumab-800CW
  NCT03938701 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
  NCT06350110 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
  NCT07138898 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Intraglandular Treatment With Adipose-derived Mesenchymal Stem Cells in Patients With Xerostomia Due to Sjögren's Disease
  NCT06805448 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• L-carnitine Supplementation in Rheumatoid Arthritis Patients
  NCT06753565 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Laser Acupuncture on Dry Eye and Sjögren's Syndrome-related Dry Eye Symptoms (LADESJS)
  NCT06780293 · Phase: Phase 2 · Ages: 20 Years to 75 Years · Sex: All (male and female) · 1 location
• Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
  NCT06998628 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Phase 1b/2 Study of IV Sarilumab in Adult With RA
  NCT07704580 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
  NCT07423533 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
  NCT01962415 · Phase: Phase 2 · Ages: 2 Months to 55 Years · Sex: All (male and female) · 2 locations
• Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases
  NCT04924270 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
  NCT07408024 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 6 locations
• Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
  NCT06828042 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
  NCT07281456 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
  NCT06428188 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 90 Years · Sex: All (male and female) · 1 location
• The Effect of Nicorandil on Rheumatoid Arthritis Patients
  NCT07730723 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients
  NCT06640309 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.